175 related articles for article (PubMed ID: 1329639)
1. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium.
Mitsuyama J; Itoh Y; Takahata M; Okamoto S; Yasuda T
Antimicrob Agents Chemother; 1992 Sep; 36(9):2030-6. PubMed ID: 1329639
[TBL] [Abstract][Full Text] [Related]
2. Activity of KB-5246 against outer membrane mutants of Escherichia coli and Salmonella typhimurium.
Kotera Y; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jul; 34(7):1323-5. PubMed ID: 2167038
[TBL] [Abstract][Full Text] [Related]
3. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.
Hirai K; Aoyama H; Irikura T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1986 Mar; 29(3):535-8. PubMed ID: 3521490
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
Barry AL; Jones RN
J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance.
Watanabe M; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1837-40. PubMed ID: 2558611
[TBL] [Abstract][Full Text] [Related]
7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
Denis A; Moreau NJ
J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.
Arguedas AG; Akaniro JC; Stutman HR; Marks MI
Antimicrob Agents Chemother; 1990 Nov; 34(11):2223-7. PubMed ID: 2073112
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of ofloxacin and tosufloxacin in fluoroquinolone-resistant E coli.
Xia PY; Feng P; Zhong L; Lv XJ; Lei BJ
Acta Pharmacol Sin; 2001 Mar; 22(3):210-4. PubMed ID: 11742566
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262).
Yazawa K; Mikami Y; Uno J
Antimicrob Agents Chemother; 1989 Dec; 33(12):2140-1. PubMed ID: 2619279
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
14. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
Gensberg K; Jin YF; Piddock LJ
FEMS Microbiol Lett; 1995 Oct; 132(1-2):57-60. PubMed ID: 7590165
[TBL] [Abstract][Full Text] [Related]
15. [Antibacterial activity of tosufloxacin against fresh clinical isolates].
Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M
Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895
[TBL] [Abstract][Full Text] [Related]
16. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
Bauernfeind A
J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
[TBL] [Abstract][Full Text] [Related]
17. Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.
Michéa-Hamzehpour M; Furet YX; Pechère JC
Antimicrob Agents Chemother; 1991 Oct; 35(10):2091-7. PubMed ID: 1662023
[TBL] [Abstract][Full Text] [Related]
18. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.
Ito T; Matsumoto M; Nishino T
Antimicrob Agents Chemother; 1995 Jul; 39(7):1522-5. PubMed ID: 7492097
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of tosufloxacin, a new quinolone antibacterial agent.
Cooper MA; Andrews JM; Wise R
J Antimicrob Chemother; 1992 Jun; 29(6):639-47. PubMed ID: 1506348
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea.
Bryan JP; Waters C; Sheffield J; Krieg RE; Perine PL; Wagner K
Antimicrob Agents Chemother; 1990 Feb; 34(2):368-70. PubMed ID: 2327784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
